This article was originally published in The Gray Sheet
Executive SummarySecond tranche of a $15 mil. private placement is complete. The sale of approximately 1.7 mil. shares at $2 each follows the Jan. 21 placement of about 5.8 mil. shares at the same price. The proceeds, in conjunction with a 30% company-wide reduction in workforce, will facilitate the continuing European roll-out of the Revelation and Revelation Tx microcatheters for therapeutic treatment of atrial fibrillation. An ongoing U.S. AF trial also will be expanded
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.